- The folks at University of Arizona are studying the effects of Pegylated liposomal doxorubicin on Breast Cancer in individuals ages 18 years and older. This clinical trial is slated to start November 2013 and is expected to end circa November 2015.520-626-2175 Dana Lewallen
This study is officially titled, "A Single Arm Phase II Trial to Assess Association of BRCA1 Protein Expression With Overall Response Rate in Patients With Metastatic Breast Cancer on Pegylated Liposomal Doxorubicin."
|Recruiting||University of Arizona Cancer Center|
Tucson, Arizona, 85742
United States - map
For more study details, please visit this link to ClinicalTrials.gov record, which is the source of this webpage.